Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0020 Transporter Info
Gene Name	SLC10A2
Transporter Name	Apical sodium-dependent bile acid transporter
Gene ID	6555
UniProt ID	Q12908

Post-Translational Modification of This DT
Overview of SLC10A2 Modification Sites with Functional and Structural Information
Sequence	M N D P N S C V D N A T V C S G A S C V V P E S N F N N I L S V V L S T V L T I L L A L V M F S M G C N V E I K K F L G H I K R P W G I C V G F L C Q F G I M P L T G F I L S V A F D I L P L Q A V V V L I I G C C P G G T A S N I L A Y W V D G D M D L S V S M T T C S T L L A L G M M P L C L L I Y T K M W V D S G S I V I P Y D N I G T S L V S L V V P V S I G M F V N H K W P Q K A K I I L K I G S I A G A I L I V L I A V V G G I L Y Q S A W I I A P K L W I I G T I F P V A G Y S L G F L L A R I A G L P W Y R C R T V A F E T G M Q N T Q L C S T I V Q L S F T P E E L N V V F T F P L I Y S I F Q L A F A A I F L G F Y V A Y K K C H G K N K A E I P E S K E N G T E P E S S F Y K A N G G F Q P D E K
PTM type	X-N-glycosylation X-Phosphorylation X-S-acylation X-Ubiquitination X: Amino Acid

N-glycosylation
Asparagine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC10A2			[1]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	10
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC10A2 Asparagine 10 has the potential to affect its expression or activity.
Unclear Residue	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC10A2			[2]
Role of PTM	Potential impacts
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-glycosylation at SLC10A2 has the potential to affect its expression or activity.
Phosphorylation
Serine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Accelerating SLC10A2 degradation			[3]
Role of PTM	Degradation via Proteosome
Modified Residue	Serine	Modified Location	335
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC10A2 Serine 335 have been reported to accelerate its degradation.
Threonine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Accelerating SLC10A2 degradation			[3]
Role of PTM	Degradation via Proteosome
Modified Residue	Threonine	Modified Location	339
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC10A2 Threonine 339 have been reported to accelerate its degradation.
Tyrosine	6 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Inhibiting the function of SLC10A2			[4]
Role of PTM	Surface Expression Modulation
Affected Drug/Substrate	Bile acids	Results for Drug	Decreasing the transport of Bile acids
Modified Residue	Tyrosine
Modified State	EPEC(Escherichia coli) infection
Studied Phenotype	Colon cancer [ICD11: 2B90]
Experimental Material(s)	Human colon carcinoma (Caco2) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Phosphorylation at SLC10A2 Tyrosine (i.e. EPEC(Escherichia coli) infection) have been reported to inhibit its transport function.
PTM Phenomenon 2	Decreasing the protein expression of SLC10A2			[5]
Role of PTM	Surface Expression Modulation
Affected Drug/Substrate	Bile acids	Results for Drug	Affecting the inward transport of bile acids
Modified Residue	Tyrosine	Modified Location	148
Modified State	Tyrosine to Phenylalanine mutation
Related Enzyme	Tyrosine-protein kinase CSK (CSK) Receptor-type tyrosine-protein phosphatase S (PTPRS)
Experimental Material(s)	African green monkey kidney fibroblast-like (COS-1) cells; Human colon carcinoma (Caco2) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Phosphorylation at SLC10A2 Tyrosine 148 (i.e. Tyrosine to Phenylalanine mutation) have been reported to decrease its protein expression.
PTM Phenomenon 3	Decreasing the protein expression of SLC10A2			[5]
Role of PTM	Surface Expression Modulation
Affected Drug/Substrate	Bile acids	Results for Drug	Affecting the inward transport of bile acids
Modified Residue	Tyrosine	Modified Location	216
Modified State	Tyrosine to Phenylalanine mutation
Related Enzyme	Tyrosine-protein kinase CSK (CSK) Receptor-type tyrosine-protein phosphatase S (PTPRS)
Experimental Material(s)	African green monkey kidney fibroblast-like (COS-1) cells; Human colon carcinoma (Caco2) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Phosphorylation at SLC10A2 Tyrosine 216 (i.e. Tyrosine to Phenylalanine mutation) have been reported to decrease its protein expression.
PTM Phenomenon 4	Decreasing the protein expression of SLC10A2			[5]
Role of PTM	Surface Expression Modulation
Affected Drug/Substrate	Bile acids	Results for Drug	Affecting the inward transport of bile acids
Modified Residue	Tyrosine	Modified Location	308
Modified State	Tyrosine to Phenylalanine mutation
Related Enzyme	Tyrosine-protein kinase CSK (CSK) Receptor-type tyrosine-protein phosphatase S (PTPRS)
Experimental Material(s)	African green monkey kidney fibroblast-like (COS-1) cells; Human colon carcinoma (Caco2) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Phosphorylation at SLC10A2 Tyrosine 308 (i.e. Tyrosine to Phenylalanine mutation) have been reported to decrease its protein expression.
PTM Phenomenon 5	Decreasing the protein expression of SLC10A2			[5]
Role of PTM	Surface Expression Modulation
Affected Drug/Substrate	Bile acids	Results for Drug	Affecting the inward transport of bile acids
Modified Residue	Tyrosine	Modified Location	311
Modified State	Tyrosine to Phenylalanine mutation
Related Enzyme	Tyrosine-protein kinase CSK (CSK) Receptor-type tyrosine-protein phosphatase S (PTPRS)
Experimental Material(s)	African green monkey kidney fibroblast-like (COS-1) cells; Human colon carcinoma (Caco2) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Phosphorylation at SLC10A2 Tyrosine 311 (i.e. Tyrosine to Phenylalanine mutation) have been reported to decrease its protein expression.
PTM Phenomenon 6	Decreasing the protein expression of SLC10A2			[5]
Role of PTM	Surface Expression Modulation
Affected Drug/Substrate	Bile acids	Results for Drug	Affecting the inward transport of bile acids
Modified Residue	Tyrosine	Modified Location	337
Modified State	Tyrosine to Phenylalanine mutation
Related Enzyme	Tyrosine-protein kinase CSK (CSK) Receptor-type tyrosine-protein phosphatase S (PTPRS)
Experimental Material(s)	African green monkey kidney fibroblast-like (COS-1) cells; Human colon carcinoma (Caco2) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Phosphorylation at SLC10A2 Tyrosine 337 (i.e. Tyrosine to Phenylalanine mutation) have been reported to decrease its protein expression.
S-acylation
Cysteine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Stabilizes hASBT to aid in its membrane expression, function, and maximal transporter flux			[6]
Role of PTM	Protein Stability
Affected Drug/Substrate	Bile acids	Results for Drug	Affecting the inward transport of bile acids
Modified Residue	Cysteine	Modified Location	314
Modified State	Cysteine to Alanine mutation
Experimental Material(s)	African green monkey kidney fibroblast-like (COS-1) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the S-acylation at SLC10A2 Cysteine 314 (i.e. Cysteine to Alanine mutation) have been reported to stabilize its protein conformation to aid in its membrane expression, function, and maximal transporter flux.
Ubiquitination
Unclear Residue	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Accelerating SLC10A2 degradation			[3]
Role of PTM	Degradation via Proteosome
Experimental Material(s)	African green monkey kidney fibroblast-like (COS-1) cells; Human colon carcinoma (Caco2) cells; Human embryonic kidney (HEK) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC10A2 have been reported to accelerate its degradation, thereby affecting its expression or activity.

References
1	Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry. 2004 Sep 14;43(36):11380-92.
2	Post-translational modifications of transporters. Pharmacol Ther. 2018 Dec;192:88-99.
3	Resveratrol promotes degradation of the human bile acid transporter ASBT (SLC10A2). Biochem J. 2014 Apr 15;459(2):301-12.
4	Enteropathogenic Escherichia coli inhibits ileal sodium-dependent bile acid transporter ASBT. Am J Physiol Gastrointest Liver Physiol. 2012 May 15;302(10):G1216-22.
5	Tyrosine Phosphorylation Regulates Plasma Membrane Expression and Stability of the Human Bile Acid Transporter ASBT ( SLC 10 A 2). Mol Pharm. 2019 Aug 5;16(8):3569-3576.
6	S-acylation status of bile acid transporter hASBT regulates its function, metabolic stability, membrane expression, and phosphorylation state. Biochim Biophys Acta Biomembr. 2021 Feb 1;1863(2):183510.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence